×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: impavido | leishmaniasis | tropical | disease

Medication Stops Parasitic Disease

Thursday, 20 March 2014 05:42 PM

Impavido (miltefosine) has been approved by the U.S. Food and Drug Administration to treat adults with leishmaniasis, a tropical disease caused by a parasite that's transmitted by the bites of sand flies.

Most Americans who contract the disease do so traveling overseas, the agency said in a news release.

The drug's safety and effectiveness were evaluated in clinical trials involving more than 700 people. Impavido's label will include a boxed warning that the medication could harm a developing fetus and shouldn't be taken by pregnant women.

Common side effects include nausea, vomiting, diarrhea, headache, loss of appetite, dizziness, abdominal pain, itching, fatigue and elevated liver enzymes, the FDA said.

The drug is produced by Paladin Therapeutics, based in Montreal.

© HealthDay


FDA-Approved-Drugs
Impavido (miltefosine) has been approved by the U.S. Food and Drug Administration to treat adults with leishmaniasis, a tropical diseasecaused by a parasite that's transmitted by the bites of sand flies. Most Americans who contract the disease do so traveling overseas, the...
impavido,leishmaniasis,tropical,disease
119
2014-42-20
Thursday, 20 March 2014 05:42 PM
Newsmax Media, Inc.
Join the Newsmax Community
Register To Comment Login To Comment
Please review Community Guidelines before posting a comment.
 
Find Your Condition
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved